Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer
When added to docetaxel in second-line therapy, the new agent improved survival in a subgroup of patients with adenocarcinoma histology. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Docetaxel | Hematology | Lung Cancer | Oral Cancer | Taxotere